Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 16/20 | 0.50 |
| ▸ | PNP | P00491 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leteprinim SCHEMBL194355 | 0.99 | HPRT1 (0.49) | HPRT1PNPLMNA | |
| Leteprinim SCHEMBL6931317 | 0.99 | HPRT1 (0.49) | HPRT1PNP | |
| Leteprinim SCHEMBL6935182 | 0.99 | HPRT1 (0.49) | HPRT1PNPLMNA | |
| Leteprinim SCHEMBL194354 | 0.89 | HPRT1 (0.48) | HPRT1PNPLMNA | |
| SCHEMBL1247298 | 0.86 | GAA (0.54) | HPRT1 | |
| SCHEMBL5258348 | 0.84 | TK1 (0.54) | HPRT1PNP | |
| Leteprinim SCHEMBL358492 | 0.83 | HSD17B10 (0.42) | LMNA | |
| SCHEMBL7684224 | 0.82 | HPRT1 (0.49) | HPRT1PNP | |
| Hydrochloric Acid SCHEMBL7438455 | 0.81 | HDAC3 (0.52) | HPRT1LMNA | |
| SCHEMBL7397072 | 0.79 | HPRT1 (0.59) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024258996-A1 | OCULAR DRUG DELIVERY | BAYLOR COLLEGE OF MEDICINE (US) | 2024-12-19 | — | — | WO | claimed |
| CN-112469406-A | Use of stearic acid for preventing or treating pulmonary fibrosis | 财团法人峨山社会福祉财团 | 2021-03-09 | — | — | CN | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014111957-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | SATYAM APPARAO (IN) | 2014-07-24 | — | — | WO | claimed |
| US-20120276019-A1 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE | DIAMEDICA INC. (CA) | 2012-11-01 | — | — | US | claimed |
| US-20110150781-A1 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE | DIAMEDICA INC. (CA) | 2011-06-23 | — | — | US | claimed |
| EP-2320939-A1 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE | Sanomune Inc. (CA) | 2011-05-18 | — | — | EP | claimed |
| EP-1790344-B1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2001036419-A1 | USE OF 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES TO STIMULATE REGENERATION OF NERVOUS TISSUE | NEOTHERAPEUTICS, INC. (US) | 2001-05-25 | — | — | WO | claimed |
| WO-2001028545-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| US-6027936-A | ADMINISTERING AMOUNT OF AT LEAST ONE MODULATING PURINE DERIVATIVE TO A MAMMAL FOR SELECTIVE INDUCTION OF GENE EXPRESSION OF MOLECULE THAT STIMULATES NEURITOGENESIS; TREATMENT AND PROPHYLAXIS FOR NERVOUS SYSTEM DISORDERS | SPECTRUM PHARMACEUTICALS, INC. | 2000-02-22 | — | — | US | claimed |
| EP-0772440-A4 | CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS | GLASKY ALVIN J (US) | 1999-05-19 | — | — | EP | claimed |
| US-5801184-A | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use | SPECTRUM PHARMACEUTICALS, INC. | 1998-09-01 | — | — | US | claimed |
| EP-0522082-B1 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | GLASKY ALVIN J (US) | 1997-07-02 | — | — | EP | claimed |
| EP-0772440-A1 | CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS | GLASKY, Alvin J. (US) | 1997-05-14 | — | — | EP | claimed |
| WO-1996003125-A1 | CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS | GLASKY ALVIN J (US) | 1996-02-08 | — | — | WO | claimed |
| US-5447939-A | Purine derivatives used for long term modification of neural activity in mammals, for treatment of mammalian neurological diseases, and for inducing long term changes in membrane potential of mammalian neuron | SPECTRUM PHARMACEUTICALS, INC. | 1995-09-05 | — | — | US | claimed |
| US-5091432-A | Synergistic | SPECTRUM PHARMACEUTICALS, INC. | 1992-02-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | HPRT1 848/4885PNP 166/4885LMNA 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.